GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Shanghai Medicilon Inc (SHSE:688202) » Definitions » Forward Dividend Yield %

Shanghai Medicilon (SHSE:688202) Forward Dividend Yield % : 0.00% (As of Jul. 10, 2025)


View and export this data going back to 2019. Start your Free Trial

What is Shanghai Medicilon Forward Dividend Yield %?

As of today (2025-07-10), the Forward Annual Dividend Yield of Shanghai Medicilon is 0.00%.

As of today (2025-07-10), the Trailing Annual Dividend Yield of Shanghai Medicilon is 0.00%.

SHSE:688202's Forward Dividend Yield % is not ranked *
in the Biotechnology industry.
Industry Median: 1.33
* Ranked among companies with meaningful Forward Dividend Yield % only.

Shanghai Medicilon's Dividends per Share for the three months ended in Mar. 2025 was ¥0.00.

During the past 12 months, Shanghai Medicilon's average Dividends Per Share Growth Rate was -100.00% per year.

The growth rate is calculated with least square regression.

For more information regarding to dividend, please check our Dividend Page.


Competitive Comparison of Shanghai Medicilon's Forward Dividend Yield %

For the Biotechnology subindustry, Shanghai Medicilon's Forward Dividend Yield %, along with its competitors' market caps and Forward Dividend Yield % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Shanghai Medicilon's Forward Dividend Yield % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Shanghai Medicilon's Forward Dividend Yield % distribution charts can be found below:

* The bar in red indicates where Shanghai Medicilon's Forward Dividend Yield % falls into.


;
;

Shanghai Medicilon Forward Dividend Yield % Calculation

Dividend Yield measures how much a company pays out in dividends each year relative to its share price.


Shanghai Medicilon  (SHSE:688202) Forward Dividend Yield % Explanation

Over the long term, the return from dividends has been a significant contributor to the total returns produced by equity securities. Studies by Elroy Dimson, Paul Marsh, and Mike Staunton of Princeton University (2002) found that a market-oriented portfolio, which included reinvested dividends, would have generated nearly 85 times the wealth generated by the same portfolio relying solely on capital gains.

Dividends may also qualify a lower tax rate for investors.

In dividends investing, Payout Ratio and Dividend Growth Rate are the two most important variables for consideration. A lower payout ratio may indicate that the company has more room to increase its dividends.

You can find the stocks that owned most by Gurus here. Or you can check out Warren Buffett's highest dividend stocks here.


Shanghai Medicilon Forward Dividend Yield % Related Terms

Thank you for viewing the detailed overview of Shanghai Medicilon's Forward Dividend Yield % provided by GuruFocus.com. Please click on the following links to see related term pages.


Shanghai Medicilon Business Description

Traded in Other Exchanges
N/A
Address
Lane 67, Libing Road, Building 5, Pilot Free Trade Zone, Shanghai, CHN, 201299
Shanghai Medicilon Inc is a comprehensive biomedical research and developemnt service company. It provides a full range of one-stop new drug development services for pharmaceutical companies and research institutions around the world in line with domestic and international reporting standards.
Executives
Chen Jin Zhang Director
Chen Guo Xing Director
Lin Zhang Qing Director
Peng Shuang Qing Core technical personnel
Li Zhi Gang Core technical personnel
Xu Yong Mei Core technical personnel
Liu Bin Bin senior management
Zhang Xiao Dong senior management
Xue Chao senior management
Ma Xing Quan senior management
Directors, senior managers, core technical personn
Cai Jin Na Directors, senior managers

Shanghai Medicilon Headlines

No Headlines